| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
10% Owner | Director | Director, 10% Owner
4 companies
Kevin P Starr last filed a Form 4 in June 2017, as Director at LRMR. The filings on record cover 4 companies. Kevin P Starr's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
At the last filing, the largest reported position was 370,323 shares of LRMR. The LRMR filings lean toward selling, a net 136,579 shares.
Kevin P Starr has 12 Form 4 filings on record from January 2015 to June 2017, across 4 companies: Director at Alnylam Pharmaceuticals (ALNY), 2015–2017; 10% Owner at CytomX Therapeutics (CTMX), 2017; 10% Owner at Editas Medicine (EDIT), 2016, and 1 more.
The 37 reported transactions were 16 other transactions, 12 open-market sales, 4 option or other derivative awards and 4 option exercises, plus smaller numbers of other types.
Counted by filing, the open-market trades come to no purchases and 4 sales worth about $14.3M.
The largest open-market sale was 75,000 shares of ALNY at an average $103.89 on November 12, 2015, about $7.8M.
Shares as reported in the last Form 4 for each company; the most recent is from June 2017. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Apr 12, 2017 | CTMX Cytomx Therapeutics, Inc. | 10% Owner | Sell | 28,357 | $16.36 | $463,792.91 | -47.4% | |
| Sep 6, 2016 | EDIT Editas Medicine, Inc. | 10% Owner | Sell | 5,890 | $15.90 | $93,665.73 | -100% | |
| Nov 12, 2015 | ALNY Alnylam Pharmaceuticals, Inc. | Director | Sale+OE | 75,000 | $103.89 | $7,792,118.26 | - | |
| Sep 24, 2015 | LRMR Larimar Therapeutics, Inc. | Director | Sell | 136,579 | $43.90 | $5,995,402.77 | -39.4% |